Opportunity
Traumatic spinal cord injury (SCI) is a profoundly debilitating condition characterized by the progressive loss of neurons and oligodendrocytes, leading to irreversible axonal damage, impaired locomotion, and compromised somatosensory function. Existing clinical management and treatment approaches for SCI patients with enduring disabilities remain largely ineffective. A significant challenge is the limited regenerative potential of adult mammalian central nervous system neurons and the hostile post-injury microenvironment, which lacks adequate neurotrophic support for restoring spinal cord integrity. While exogenous grafts containing therapeutic cell populations, such as neural progenitor cells (NPCs), have shown promise, their efficacy is often constrained. Current approaches typically require embedding NPCs in a fibrin-thrombin matrix with neurotrophic factors to support survival and differentiation at the injury site. However, therapeutic outcomes are limited by the prolonged maturation process of human NPCs (hNPCs) and the hostile niche that often promotes graft differentiation into astrocytes rather than neurons. Furthermore, SCI leads to the formation of a glial scar, creating a physical and chemical barrier that prevents regenerated axons from penetrating and projecting across the lesion site. Therefore, there is a critical unmet need for an advanced therapeutic strategy that employs genetically modified hNPCs with enhanced survival, superior neuronal differentiation capacity, and the ability to modulate the hostile host environment to effectively treat traumatic SCI.
Technology
The present invention addresses the existing problems by providing methods and compositions centered on genetically engineered neural progenitor cells (NPCs). The core innovation involves the genetic modification of human NPCs to intrinsically upregulate the sonic hedgehog (SHH) signaling pathway. This is specifically achieved by suppressing a key negative regulator of the SHH pathway, namely the suppressor of fused homolog (SUFU). The suppression of SUFU, for example via knockdown using short hairpin RNAs (shRNAs), leads to the activation of SHH signaling within the NPCs themselves. This intrinsic activation confers several critical advantages: it enhances the survival of the engineered NPCs, promotes their differentiation into therapeutic cell types (specifically neurons, including motor neurons, and oligodendrocytes), and reduces their susceptibility to apoptosis, even in the absence of extrinsic neurotrophic factors which are typically deficient in the injured spinal cord. Remarkably, these SUFU-knockdown (SUFU-KD) NPCs also exert non-cell autonomous effects by secreting SHH protein into the extracellular environment. This secreted SHH modulates the hostile injury niche by enhancing the survival and neurogenesis of surrounding host cells and non-modified NPCs, and by reducing the formation of inhibitory barriers such as those formed by glial scar components like chondroitin sulfate proteoglycans (CSPGs). The technology involves administering these genetically engineered NPCs, for instance by direct grafting into the spinal cord lesion site. The grafts effectively integrate into the host tissue, extend axons over long distances beyond the glial scar, establish synaptic connections with host neural circuits, and promote the remyelination of axons. This combinatorial approach of intrinsic SHH pathway activation and extrinsic SHH protein secretion provides a powerful solution to overcome the limitations of previous cell therapies for SCI.
Advantages
- Enhances the intrinsic survival and reduces apoptosis of grafted neural progenitor cells in the hostile spinal cord injury environment.
- Promotes robust and preferential differentiation of grafted cells into therapeutic neuronal subtypes (e.g., motor neurons, glycinergic/GABAergic inhibitory neurons, excitatory neurons) and oligodendrocytes, even without supplemental neurotrophic factors.
- Exerts beneficial non-cell autonomous effects by secreting SHH protein, which improves the survival and differentiation of neighboring host cells and non-engineered grafts.
- Modulates the inhibitory injury microenvironment by reducing the deposition of glial scar components like CSPGs and attenuating the dense astrocytic barrier (GFAP+), facilitating axonal outgrowth and integration.
- Enables long-distance axonal projection from the graft into the host spinal cord, surpassing the lesion site.
- Promotes remyelination of axons, which is crucial for restoring neural signal conduction.
- Facilitates effective synaptic integration with the host's existing neural circuitry, including connections from descending motor pathways.
- Leads to significant and superior functional recovery in locomotor tests (e.g., BBB scores, grid walking, footprint analysis) in animal models of contusive SCI compared to control grafts.
Applications
- Treatment of traumatic spinal cord injuries resulting from compression, contusion, or laceration.
- Development of cell-based therapies for central nervous system (CNS) repair and regeneration.
- Use as a research tool for studying SHH signaling, neural differentiation, and spinal cord injury mechanisms.
- Potential application in combinatorial therapies, such as co-administration with neurotrophic factors or integration with physical rehabilitation regimens.
- Formulation as an injectable cell suspension, gel, or scaffold for controlled and localized delivery to the CNS lesion site.
- Basis for personalized medicine approaches using patient-derived induced pluripotent stem cells (iPSCs) to generate autologous SUFU-modified NPC grafts.
